CONSIDERATIONS TO KNOW ABOUT JEMPERLI VS KEYTRUDA ENDOMETRIAL CANCER

This prevents the activation from the T-cell which normally would target and destroy cancer. The cancer cells can then multiply and distribute. When Keytruda binds towards the PD-1 receptor it stops cancer cells from linking to and inactivating T-cells, allowing T-cell re-activation, and boosting the immune system's response against cancer. This af